PDS Biotechnology

NetScientific plc (“NetScientific” or the “Company”) Portfolio Company PDS Biotechnology announces new positive data for lead immunotherapy treatment in high-risk human papillomavirus (HPV)   London, UK – 19 September 2019 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, is pleased to note the new data announced today by portfolio company, PDS Biotechnology (Nasdaq: PDSB), following a post-hoc follow up of its …

1 August 2019 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Corporation Reports Second Quarter 2019 Financial Results   NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) has released its unaudited financial results for the second …

31 July 2019 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Corporation liquidity funding program NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq:PDSB) has announced a liquidity funding program with Aspire Capital Fund, LLC (“Aspire”), an Illinois …

16 May 2019 NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology journal publication   NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq:PDSB) has announced a peer-reviewed publication supporting the novel mechanisms of action of PDS’s proprietary Versamune® platform in cancer immunotherapy.   The article “Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles …

19 March 2019 NetScientific plc (“NetScientific” or the “Company”) PDS merger with Edge Therapeutics update Further to its announcements on 26 November 2018 and 18 March 2019, the Company announces that its ownership of the enlarged PDS Biotechnology Corporation (“PDS”), trading on Nasdaq under the ticker PDSB, on a fully-diluted basis is 8.15%, which at the listing price on 18 March 2019 of …

Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer Growing product pipeline utilising Versamune®, a novel, versatile, multi-functional platform Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and favourable safety profile in early stage cervical cancer Combined company plans to initiate multiple Phase 2b/3 clinical trials of PDS0101 in HPV-associated cancers …

London, UK – July 10th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, announces a new clinical trial collaboration agreement between its portfolio company PDS Biotechnology Corporation (“PDS”) and a subsidiary of Merck & Co., Inc. (known as MSD outside the United States and Canada). The agreement will enable PDS to evaluate the combination of its Versamune®-based PDS0101 …

RNS Number : 0007V NetScientific PLC 13 April 2016 NetScientific plc (“NetScientific” or the “Company” or the “Group”)   NetScientific Portfolio Company PDS Biotechnology will embark on multiple Phase 2 studies following positive results following the completion of its Phase I study for PDS0101 Immunotherapy for HPV-Related Cancers   London, UK – 13/4/2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is pleased …

RNS Number : 5158O NetScientific PLC 09 February 2016   NetScientific plc PDS Biotechnology partners with National Cancer Institute in Phase II clinical trials for novel cancer immunotherapies London, UK – 9 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, is pleased to note that one of its portfolio companies, PDS Biotechnology, has signed …

RNS Number : 4379M NetScientific PLC 20 January 2016 NetScientific plc   PDS Biotechnology appoints Chief Medical Officer and VP of Drug Development and Manufacturing to drive its clinical programmes   London, UK – 20 January 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes that its portfolio company, PDS Biotechnology, has appointed Dr. Robert Shepard, …

RNS Number : 7136Z NetScientific PLC 15 December 2014   NetScientific plc (‘NetScientific’ or ‘the Group’)    NetScientific Invests in Next Generation, Immunotherapeutics Company, PDS Biotechnology   15 December 2014: NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced it has made an investment in PDS Biotechnology Corporation (‘PDS’).   PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more …